Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...
The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...
Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...
ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results